Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: Refining the biochemical markers of mild disease activity

Hormone and Metabolic Research

Volumn 42, Issue 1, 2010, Pages 50-55

  Elias, P C L ^a   Lugao, H B ^a   Pereira, M C ^a   MacHado, H R ^a   De Castro, M ^a   Moreira, A C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acromegaly; GH; IGF I

Indexed keywords

BIOCHEMICAL MARKER; GLUCOCORTICOID; GLUCOSE; GROWTH HORMONE; LEVOTHYROXINE; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HYPOGONADISM; IMMUNOASSAY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; REMISSION; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED;

EID: 73949148218     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1239522     Document Type: Article

References (35)

1. Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am 2008 37 101-122
2. Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis 2008 3 17
3. Clemmons DR, Strasburger C. Monitoring the response to treatment in acromegaly. J Clin Endocrinol Metab 2004 89 5289-5291
4. Wood P. Growth hormone: Its measurement and the need for assay harmonization. Ann Clin Biochem 2001 38 471-482
5. Bidlingmaier M, Strasburger CJ. Growth hormone assays: Current methodologies and their limitations. Pituitary 2007 10 115-119
6. Trainer PJ, Barth J, Sturgeon C, Wieringaon G. Consensus statement on the standardisation of GH assays. Eur J Endocrinol 2006 155 1-2
7. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S. Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 2000 85 526-529
8. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998 83 3808-3816
9. Costa AC, Rossi A, Martinelli Jr CE, Machado HR, Moreira AC. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: Should we achieve strict normal GH levels for a biochemical cure? J Clin Endocrinol Metab 2002 87 3142-3147
10. Gullu S, Keles H, Delibasi T, Tonyukuk V, Kamel N, Erdogan G. Remission criteria for the follow-up of patients with acromegaly. Eur J Endocrinol 2004 150 465-471
11. Trainer PJ. Editorial: Acromegaly consensus, what consensus? J Clin Endocrinol Metab 2002 87 3534-3536
12. Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res 2003 13 171-184
13. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002 87 4054-4058
14. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A. Guidelines for acromegaly management: An update. J Clin Endocrinol Metab 2009 94 1509-1517
15. Vierhapper H, Heinze G, Gessl A, Exner M, Bieglmayr C. Use of the oral glucose tolerance test to define remission in acromegaly. Metabolism 2003 52 181-185
16. Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 2005 90 1972-1978
17. Vieira JG, Ando MH, Nishida SK, Macedo CD, Abucham JZ. Clinical utility of a 22-kda growth hormone-specific assay. Braz J Med Biol Res 1992 25 243-245
18. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999 8 135-160
19. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989 45 255-268
20. Ho KY, Weissberger AJ. Characterization of 24-h growth hormone secretion in acromegaly: Implications for diagnosis and therapy. Clin Endocrinol (Oxf) 1994 41 75-83
21. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, Sabin I, Jenkins JP, Chew SL, Monson JP, Besser GM, Grossman AB. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 2001 86 1645-1652
22. Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, Spranger J, Strasburger CJ, Schofl C, Pfeiffer AF. Growth hormone response during oGTT: The impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls and the role of gender, age, and BMI. J Clin Endocrinol Metab 2008 93 1254-1262
23. Espinosa-de-Los-Monteros AL, Sosa E, Cheng S, Ochoa R, Sandoval C, Guinto G, Mendoza V, Hernandez I, Molina M, Mercado M. Biochemical evaluation of disease activity after pituitary surgery in acromegaly: A critical analysis of patients who spontaneously change disease status. Clin Endocrinol (Oxf) 2006 64 245-249
24. Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 2008 94 523-527
25. Semer M, Faria AC, Nery M, Salgado LR, Knoepfelmacher M, Wajchenberg BL, Liberman B. Growth hormone pulsatility in active and cured acromegalic subjects. J Clin Endocrinol Metab 1995 80 3767-3770
26. van den Berg G, Veldhuis JD, Frolich M, Roelfsema F. An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 1996 81 2460-2467
27. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of Abnormal nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab 2004 89 495-500
28. Sherlock M, Aragon Alonso A, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM. Monitoring disease activity using growth hormone and insulin like growth factor-I in the follow up of 501 patients with acromegaly. Clin Endocrinol 2008 71 74-81
29. Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, Cappabianca P, Lombardi G. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clin Endocrinol (Oxf) 2006 65 250-256
30. Peacey SR, Toogood AA, Veldhuis JD, Thorner MO, Shalet SM. The relationship between 24-h growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: Impact of surgery or radiotherapy. J Clin Endocrinol Metab 2001 86 259-266
31. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: Implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002 87 3537-3542
32. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A. Consensus statement: Medical management of acromegaly. Eur J Endocrinol 2005 153 737-740
33. Ayuk J, Sheppard MC. Does acromegaly enhance mortality? Rev Endocr Metab Disord 2008 9 33-39
34. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008 159 89-95
35. Bajuk Studen K, Barkan A. Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: Reliability of different sampling models. J Clin Endocrinol Metab 2008 93 491-496